<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02644889</url>
  </required_header>
  <id_info>
    <org_study_id>EGFR2015-02</org_study_id>
    <nct_id>NCT02644889</nct_id>
  </id_info>
  <brief_title>EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment</brief_title>
  <official_title>Epidermal Growth Factor Receptor (EGFR) Mutation Detection From Advanced Non-small Cell Lung Cancer Tissue and Plasma in Tyrosine Kinase Inhibitor (TKI) Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GenoSaber</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GenoSaber</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has been designed in order to detect EGFR mutation abundance of tissue and&#xD;
      concentration of plasma from Advanced Non-small Cell Lung Cancer during treatment with&#xD;
      Tyrosine Kinase Inhibitor (TKI) .Through this experiment the investigators aim to evaluate&#xD;
      the feasibility of plasma EGFR detection and evaluate the correlation of EGFR mutations and&#xD;
      prognosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>EGFR Mutation Detection of FFPE and plasma samples</measure>
    <time_frame>baseline</time_frame>
    <description>To evaluate the feasibility of plasma EGFR detection from non-small cell lung cancer patients harboring EGFR activating mutation who are being treated with EGFR TKIs and evaluate the correlation of EGFR mutations and prognosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EGFR Mutation Detection of plasma samples for the following-up patients who take TKI.</measure>
    <time_frame>From start of treatment to time of progression or death, whichever occurs first, assessed up to 3 years</time_frame>
    <description>In order to monitor the change of plasma EGFR mutation copy number.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Patients advanced NSCLC EGFR mutated</arm_group_label>
    <description>This is an observational study, there is no intervention.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with stage Ⅲ-Ⅳ NSCLC with EGFR mutations and who began a treatment by TKI .&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age older than 18 years and under 75 years&#xD;
&#xD;
          -  Histologically and cytologically proven non-small Cell Lung Cancer&#xD;
&#xD;
          -  Clinical stages Ⅲ ~ Ⅳ&#xD;
&#xD;
          -  Not receive any anti-tumor treatment&#xD;
&#xD;
          -  Eastern cooperative oncology group performance status (ECOG PS) =1~2&#xD;
&#xD;
          -  Estimated survival time more than 3 months&#xD;
&#xD;
          -  EGFR-TKI treatment for first-line or second-line&#xD;
&#xD;
          -  Voluntary to participate in this clinical trial and sign the consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients have received EGFR-TKI therapy before the study&#xD;
&#xD;
          -  With other malignancy history in the recent 5 years before the study&#xD;
&#xD;
          -  Pregnancy or breast feeding phase&#xD;
&#xD;
          -  Inadequate samples for testing&#xD;
&#xD;
          -  Follow-up compliance is poor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>December 28, 2015</study_first_submitted>
  <study_first_submitted_qc>December 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2016</study_first_posted>
  <last_update_submitted>January 6, 2016</last_update_submitted>
  <last_update_submitted_qc>January 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epidermal growth factor receptor(EGFR)</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

